Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Complementary Medicine and Therapies
Published in: BMC Complementary Medicine and Therapies 1/2021

Open Access 01-12-2021 | Research article

Efficacy and safety of Si-Jun-Zi-Tang-based therapies for functional (non-ulcer) dyspepsia: a meta-analysis of randomized controlled trials

Authors: Yaping Wang, Bin Liu, Xiuqiong Fu, Tiejun Tong, Zhiling Yu

Published in: BMC Complementary Medicine and Therapies | Issue 1/2021

Login to get access

Abstract

Background

The traditional Chinese medicine formula Si-Jun-Zi-Tang (SJZT) has a long history of application in the treatment of functional dyspepsia (non-ulcer dyspepsia, FD)-like symptoms. SJZT-based therapies have been claimed to be beneficial in managing FD. This study aimed to assess the efficacy and safety of SJZT-based therapies in treating FD by meta-analysis.

Methods

Systematic searches for RCTs were conducted in seven databases (up to February 2019) without language restrictions. Data were analyzed using Cochrane RevMan software version 5.3.0 and Stata software version 13.1, and reported as relative risk (RR) or odds ratio (OR) with 95% confidence intervals (CIs). The primary outcome was response rate and the secondary outcomes were gastric emptying, quality of life, adverse effects and relapse rate. The quality of evidence was evaluated according to criteria from the Cochrane risk of bias.

Results

A total of 341 potentially relevant publications were identified, and 12 RCTs were eligible for inclusion. For the response rate, there was a statically significant benefit in favor of SJZT-based therapies (RR = 1.23; 95% CI 1.17 to 1.30). However, the benefit was limited to modified SJZT (MSJZT). The relapse rate of FD patients received SJZT-based therapies was lower than that of patients who received conventional medicines (OR = 0.23; 95% CI 0.10 to 0.51). No SJZT-based therapies-related adverse effect was reported.

Conclusion

SJZT-based prescriptions may be effective in treating FD and no serious side-effects were identified, but the effect on response rate appeared to be limited to MSJZT. The results should be interpreted with caution as all the included studies were considered at a high risk of bias. Standardized, large-scale and strictly designed RCTs are needed to further validate the benefits of SJZT-based therapies for FD management.

Trial registration

Systematic review registration: [PROSPERO registration: CRD42019139136].
Literature
1.
Stanghellini V, Chan FK, Hasler WL, Malagelada JR, Suzuki H, Tack J, et al. Gastroduodenal disorders. Gastroenterology. 2016;6:1380–92.CrossRef
2.
Aro P, Talley NJ, Ronkainen J, Storskrubb T, Vieth M, Johansson SE, et al. Anxiety is associated with uninvestigated and functional dyspepsia (Rome III criteria) in a Swedish population-based study. Gastroenterology. 2009;1:94–100.CrossRef
3.
Kaji M, Fujiwara Y, Shiba M, Kohata Y, Yamagami H, Tanigawa T, et al. Prevalence of overlaps between GERD, FD and IBS and impact on health-related quality of life. J Gastroenterol Hepatol. 2010;6:1151–6.CrossRef
4.
Agréus L, Svärdsudd K, Talley NJ, Jones MP, Tibblin G. Natural history of gastroesophageal reflux disease and functional abdominal disorders: a population-based study. Am J Gastro. 2001;10:2905.CrossRef
5.
Halder SL, Locke GR, Schleck CD, Zinsmeister AR, Melton LJ, Talley NJ. Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology. 2007;3:799–807.CrossRef
6.
Ford A, Forman D, Bailey A, Axon A, Moayyedi P. Fluctuation of gastrointestinal symptoms in the community: a 10-year longitudinal follow-up study. Aliment Pharm Therap. 2008;8:1013–20.CrossRef
7.
Mazzoleni LE, Sander GB, de Magalhães Francesconi CF, Mazzoleni F, Uchoa DM, De Bona LR, et al. Helicobacter pylori eradication in functional dyspepsia: HEROES trial. Arch Intern Med. 2011;21:1929–36.CrossRef
8.
Iwakiri R, Tominaga K, Furuta K, Inamori M, Furuta T, Masuyama H, et al. Randomised clinical trial: rabeprazole improves symptoms in patients with functional dyspepsia in Japan. Aliment. Pharm. Therap. 2013;7:729–40.CrossRef
9.
Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006;4:CD001960.
10.
Talley NJ, Locke GR, Saito YA, Almazar AE, Bouras EP, Howden CW, et al. Effect of amitriptyline and escitalopram on functional dyspepsia: a multicenter, randomized controlled study. Gastroenterology. 2015;2:340–9.CrossRef
11.
Orive M, Barrio I, Orive V, Matellanes B, Padierna J, Cabriada J, et al. A randomized controlled trial of a 10 week group psychotherapeutic treatment added to standard medical treatment in patients with functional dyspepsia. J Psychosom Res. 2015;6:563–8.CrossRef
12.
Lee K-J, Kindt S, Tack J. Pathophysiology of functional dyspepsia. Best Pract Res Cl Gastro. 2004;4:707–16.CrossRef
13.
Bosco D, Plastino M, Marcello MG, Mungari P, Fava A. Acute hemifacial dystonia possibly induced by clebopride. Clin Neuropharmacol. 2009;2:107–8.CrossRef
14.
Shin HW, Chung SJ. Drug-induced parkinsonism. J Clin Neurol. 2012;1:15–21.CrossRef
15.
Quigley EM. Prokinetics in the management of functional gastrointestinal disorders. J Neurogastroenterol Motil. 2015;3:330.CrossRef
16.
Leelakanok N, Holcombe A, Schweizer ML. Domperidone and risk of ventricular arrhythmia and cardiac death: a systematic review and meta-analysis. Cl Drug Invest. 2016;2:97–107.CrossRef
17.
Dossett ML, Davis RB, Lembo AJ, Yeh GY. Complementary and alternative medicine use by US adults with gastrointestinal conditions: results from the 2012 National Health Interview Survey. Am J Gastro. 2014;11:1705–11.CrossRef
18.
Hung A, Kang N, Bollom A, Wolf JL, Lembo A. Complementary and alternative medicine use is prevalent among patients with gastrointestinal diseases. Digest Dis Sci. 2015;7:1883–8.CrossRef
19.
Vlieger AM, Blink M, Tromp E, Benninga MA. Use of complementary and alternative medicine by pediatric patients with functional and organic gastrointestinal diseases: results from a multicenter survey. Pediatrics. 2008;2:446–51.CrossRef
20.
Zhang S, Chen Z, Xu W, Wang HB. Study on distribution characteristic of syndrome of 565 cases of functional dyspepsia by twice differentiation of symptoms and signs based on the ‘cold, heat, deficiency, excess’. Chin J Tradit Chin Med Pharm. 2008;9:833–4.
21.
Zhang S, Wang H, Li Q. Chinese consensus on diagnosis and treatment of functional dyspepsia. Chin J Integr Tradit West Med Dig. 2010;30:533–7.
22.
Arumugam S, Watanabe K. Japanese kampo medicines for the treatment of common diseases: focus on inflammation: Academic; 2017. P.192.
23.
Liu JY. Taipping Huimin Hejijufang. Beijing: People’s Medical Publishing House; 2007.
24.
Ji YF, Wang RJ, Li XB. Research progress on chemical constituents and pharmacological effects of Sijunzi decoction. Chin Tradit Herb Drugs. 2016;5:837–43.
25.
Wang YL, Wang Y. Effects of Sijunzi dripping pill on gastrointestinal motility of mice. Chin Herb Med. 2014;2:120–4.CrossRef
26.
Drossman DA. The functional gastrointestinal disorders: diagnosis, pathophysiology, and treatment: a multinational consenus. Boston: Little brown; 1994.
27.
28.
Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006;5:1377–90.CrossRef
29.
Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features, and Rome IV. Gastroenterology. 2016;6:1262–79.CrossRef
30.
31.
Deng YB, Su R. Effective observation on treating functional dyspepsia with different dosage four gentlemen decoction with the card. Clin J Chinese Med. 2010;7:82–9.
32.
Hu JF. Clinical observation on Jiawei Sijunzi decoction in treating functional dyspepsia. Hubei: Hubei University of Chinese Medicine; 2001.
33.
Cao JG. Treating 49 cases of functional dystrophy of spleen deficiency and liver stagnation with Jiawei Sijunzi decoction. Chin. J Integr Tradit Western Med Digestion. 2008;2:126–8.
34.
Li YH. Clinical observation on treatment of spleen and stomach eeak type functional dyspepsia with Sijunzi decoction. Beijing J Tradit Chin Med. 2008;10:806–7.
35.
Mu DC. Effect of Sijunzi decoction in the treatment of functional dyspepsia. Modern Med J Chin. 2012;5:68–9.
36.
Zhang ZY. Clinical observation on the treatment of functional dyspepsia with Xiaopi Sanjie method. Chin J Med Guide. 2013;S1:161–2.
37.
Lv L. Study of the clinical observation and experiments on treating distention and fullness disease (functional dyspepsia) with the invigorating spleen method of traditional Chinese medicine. Guangzhou: Guangzhou University of Chinese Medicine; 2014.
38.
Zhang W. Study of the clinical observation and experiments on treating functional dyspepsia (FD) of spleen deficiency with the decoction of Sijunizijiawei. Guangzhou: Guangzhou University of Chinese Medicine; 2014.
39.
Lan HB, Yuan HP. Effect of Jiawei Sijunzi decoction on functional dyspepsia of spleen deficiency type. Chin J Urban Rural Enterp Hyg. 2016;7:84–5.
40.
Liu HB, Liu FX, Zhang W. Clinical efficacy of Xiangsha Sijunzi decoction combined with domperidone in the treatment of functional dyspepsia with spleen deficiency and qi stagnation. J Med Front. 2016;15:336–7.
41.
Li RF. Treatment of 68 cases of functional dyspepsia with sijunzi decoction. Guide Chin Med. 2016;23:187–8.
42.
Chen MH, Li YH, Zhou JG, Hu W. Textual research and pharmacological analysis of partly functional replacing Panax Ginseng with Codonopsis Pilosula. J China Three Gorges Univ (Natural Sciences). 2016;5:110–2.
43.
Wang Z, Ng T, Yeung H, Xu G. Immunomodulatory effect of a polysaccharide-enriched preparation of Codonopsis pilosula roots. Gen Pharmac. 1996;8:1347–50.CrossRef
44.
Tack J, Caenepeel P, Fischler B, Piessevaux H, Janssens J. Symptoms associated with hypersensitivity to gastric distention in functional dyspepsia. Gastroenterology. 2001;3:526–35.CrossRef
45.
Sarnelli G, Caenepeel P, Geypens B, Janssens J, Tack J. Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. Am J Gastro. 2003;4:783–8.CrossRef
46.
Shindo T, Futagami S, Hiratsuka T, Horie A, Hamamoto T, Ueki N, et al. Comparison of gastric emptying and plasma ghrelin levels in patients with functional dyspepsia and non-erosive reflux disease. Digestion. 2009;2:65–72.CrossRef
47.
Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology. 1998;6:1346–52.CrossRef
48.
Suzuki H, Moayyedi P. Helicobacter pylori infection in functional dyspepsia. Nat Rev Gastro Hep. 2013;3:168–74.CrossRef
49.
Yamawaki H, Futagami S, Shimpuku M, Sato H, Wakabayashi T, Maruki Y, et al. Impact of sleep disorders, quality of life and gastric emptying in distinct subtypes of functional dyspepsia in Japan. J Neurogastro Motil. 2014;1:104–12.CrossRef
50.
Madisch A, Andresen V, Enck P, Labenz J, Frieling T, Schemann M. The diagnosis and treatment of functional dyspepsia. Deutsch Aerztebl Intern. 2018;13:222–32.
51.
Zhong ZS, Huang HP, Zhang W, Lin XF, Zhong RM, Ge YH, et al. Disorder in CNP-NPRB-cGMP pathway of gastric antral smooth muscle of functional dyspepsia model rats with spleen-deficiency syndrome and intervening mechanism of Sijunzi tang. Chin J Exp Tradit Med Formulae. 2017;13:133–7.
52.
Song HP, Li RY, Wei YX, Li X, Yu HH, Yuan ZY, et al. Effect of Sijunzi tang in promoting migration and proliferation of small intestinal epithelial cells by up-regulating c-Myc expression. Chin J Exp Tradit Med Formulae. 2016;22:154–9.
53.
Tu XH. Studies on the effects of Sijunzi decoction polysaccharide on polyamines-mediated calcium signaling pathway during intestinal epithelial cell migration. Guangzhou: Guangzhou University of Chinese Medicine; 2016.
54.
Holtmann G, Talley NJ, Liebregts T, Adam B, Parow C. A placebo-controlled trial of itopride in functional dyspepsia. New Engl J Med. 2006;8:832–40.CrossRef
55.
Vakil NB, Howden CW, Moayyedi P, Tack J. White Paper AGA: Functional dyspepsia. Clin Gastroenterol Hepatol 2017;8:1191–1194.
56.
Cheng CW, Wu TX, Shang HC, Li YP, Altman DG, Moher D, et al. CONSORT extension for Chinese herbal medicine formulas 2017: recommendations, explanation, and elaboration. Ann Intern Med. 2017;2:112–21.CrossRef
Metadata
Title
Efficacy and safety of Si-Jun-Zi-Tang-based therapies for functional (non-ulcer) dyspepsia: a meta-analysis of randomized controlled trials
Authors
Yaping Wang
Bin Liu
Xiuqiong Fu
Tiejun Tong
Zhiling Yu
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2021
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-020-03176-z

Other articles of this Issue 1/2021

BMC Complementary Medicine and Therapies 1/2021 Go to the issue

Research

Ameliorated biomechanical properties of carotid arteries by puerarin in spontaneously hypertensive rats

Research

The effect of a mindfulness-based stress intervention on neurobiological and symptom measures in adolescents with early life stress: a randomized feasibility study

Research article

Ethanolic extract of Nymphaea lotus L. (Nymphaeaceae) leaves exhibits in vitro antioxidant, in vivo anti-inflammatory and cytotoxic activities on Jurkat and MCF-7 cancer cell lines

Research

Bio-guided bioactive profiling and HPLC-DAD fingerprinting of Ukrainian saffron (Crocus sativus stigmas): moving from correlation toward causation

Research

Crude extract and isolated bioactive compounds from Notholirion thomsonianum (Royale) Stapf as multitargets antidiabetic agents: in-vitro and molecular docking approaches

Research article

Antifungal and anti-biofilm activity of a new Spanish extract of propolis against Candida glabrata